Escitalopram - A review of its use in the management of anxiety disorders

被引:37
作者
Dhillon, Sohita [1 ]
Scott, Lesley J. [1 ]
Plosker, Greg L. [1 ]
机构
[1] Adis Int Ltd, Auckland 1311, New Zealand
关键词
D O I
10.2165/00023210-200620090-00010
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Escitalopram (Cipralex (R), Lexapro (R), Seroplex (R), Sipralexa (R)), the therapeutically active S-enantiomer of racemic citalopram (RS-citalopram), is a potent and highly selective serotonin reuptake inhibitor. It is effective and generally well tolerated in the treatment of moderate to severe generalised anxiety disorder (GAD) or social anxiety disorder (SAD), panic disorder (with or without agoraphobia) as well as obsessive-compulsive disorder (OCD). Moreover, escitalopram is at least as effective as paroxetine for the treatment of GAD, SAD or OCD and appears to achieve a more rapid response than racemic citalopram in the management of panic disorder. Generally, it has a more favourable tolerability profile than paroxetine in terms of fewer discontinuation symptoms. In addition, a favourable pharmacokinetic profile permits once-daily administration of the drug. Additional comparative studies are required to definitively position escitalopram with respect to other SSRIs and venlafaxine. Nevertheless, available clinical data indicate that escitalopram is an effective first-line treatment option for the management of GAD, SAD, panic disorder and OCD.
引用
收藏
页码:763 / 790
页数:28
相关论文
共 82 条
[71]   Escitalopram versus paroxetine for social anxiety disorder: An analysis of efficacy for different symptom dimensions [J].
Stein, DJ ;
Andersen, EW ;
Lader, M .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 (01) :33-38
[72]  
STEIN DJ, 2006, ESCITALOPRAM TREATME
[73]   R-citalopram functionally antagonises escitalopram in vivo and in vitro:: evidence for kinetic interaction at the serotonin transporter [J].
Stórustovu, SI ;
Sánchez, C ;
Pörzgen, P ;
Brennum, LT ;
Larsen, AK ;
Pulis, M ;
Ebert, B .
BRITISH JOURNAL OF PHARMACOLOGY, 2004, 142 (01) :172-180
[74]   Managing depressive and anxiety disorders with escitalopram [J].
Thase, ME .
EXPERT OPINION ON PHARMACOTHERAPY, 2006, 7 (04) :429-440
[75]   Regional pattern of binding and c-Fos induction by (R)- and (S)-citalopram in rat brain [J].
Thomsen, C ;
Helboe, L .
NEUROREPORT, 2003, 14 (18) :2411-2414
[76]   Early life trauma decreases glucocorticoid receptors in rat dentate gyrus upon adult re-stress: Reversal by escitalopram [J].
Uys, JDK ;
Muller, CJF ;
Marais, L ;
Harvey, BH ;
Stein, DJ ;
Daniels, WMU .
NEUROSCIENCE, 2006, 137 (02) :619-625
[77]  
Valuck R., 2004, PHARMACOL THER DENT, V29, P234
[78]  
Von Moltke LL, 2001, DRUG METAB DISPOS, V29, P1102
[79]   A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression [J].
Wagner, KD ;
Jonas, J ;
Findling, RL ;
Ventura, D ;
Saikali, K .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2006, 45 (03) :280-288
[80]   Escitalopram - A review of its use in the management of major depressive and anxiety disorders [J].
Waugh, J ;
Goa, KL .
CNS DRUGS, 2003, 17 (05) :343-362